Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Dge6.0
Verdauungsenzyme – Forschung
Hilft wahrscheinlich
29 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Verdauungsenzyme scheint in 5 von 5 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2006–2026 mit einer typischen Studiengröße von 39 Teilnehmenden.
Basierend auf 29 Studien · 1 Meta-Analyse · 16 RCTs · 902 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Was die Studien gefunden haben
5geholfen· 24 weitere ohne bewertete Effektdaten
Nach Outcome
Pancreatic insufficiency & GI symptomsReduziertes Blähungsgefühl und verbesserte Nahrungsmittelverträglichkeit innerhalb von 1-2 Wochen · 1-2 Wochen
Hilft wahrscheinlich24 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung6 Studien
Glucose & metabolic
Zu wenige bewertete Studien2 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Liver health
Zu wenige bewertete Studien1 Studie
Weight management
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 13 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
902
typische Studie: 39 Personen
Stärkste Designs
17
1 gepoolt, 16 randomisiert
Zeigte Nutzen
100%
5/5 Studien
Wie lange Studien liefen
3+ Monate
2
Untersuchte Populationen
Patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery2
Chronic pancreatitis patients1
Children with ASD1
Functional dyspepsia patients1
Aktives Forschungsgebiet
11 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2017
200620162026
1Coefficient of fat absorptionMeta-Analysen=511 · large study2017
Einfach gesagt: PERT is indicated to correct EPI and malnutrition in CP and may be improved by higher doses, enteric coating, administration during food and acid suppression.
de la Iglesia-García D et al. · Gut (2017)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
PERT improved CFA compared with baseline (83.7±6.0 vs 63.1±15.0, p<0.00001; I2=89%) and placebo (83.2±5.5 vs 67.4±7.0, p=0.0001; I2=86%).
PERT is indicated to correct EPI and malnutrition in CP and may be improved by higher doses, enteric coating, administration during food and acid suppression.
Further studies are required to determine optimal regimens, the impact of health inequalities and long-term effects on nutrition.
Einfach gesagt: The results also found that the main interventions used were dietary interventions and nutraceuticals, including targeted supplements, vitamins and minerals, omega 3 s and prebiotics, probiotics and digestive enzymes.
Doherty M et al. · Journal of autism and developmental disorders (2025)
The results of this systematic review identified that for autistic people, vitamin and mineral supplements may only be of benefit if there is a deficiency.
The results also found that the main interventions used were dietary interventions and nutraceuticals, including targeted supplements, vitamins and minerals, omega 3 s and prebiotics, probiotics and digestive enzymes.
Einfach gesagt: Therapeutic intervention, which may consist of supplementation of pancreatic enzymes and/or vitamins in aged individuals with proven exocrine pancreas insufficiency, could contribute to healthy ageing.
Löhr JM et al. · Journal of internal medicine (2018)
Five per cent of people older than 70 years and ten per cent older than 80 years have pancreatic exocrine insufficiency (PEI) with a faecal elastase-1 below 200 μg g-1 stool, and 5% have severe PEI with faecal elastase-1 below 100 μg g-1 stool.
Malnutrition consists of deficits of fat-soluble vitamins and is affecting both patients with PEI and the elderly.
Secondary consequences may include decreased bone mineral density and results from impaired absorption of fat-soluble vitamin D due to impaired pancreatic exocrine function.
15Fat and protein absorptionRCTn=36 · small study2016
Einfach gesagt: Pancrelipase improved fat and protein absorption in patients with EPI due to chronic pancreatitis or pancreatectomy, with or without DM, and matched the safety profile previously reported.
Whitcomb DC et al. · Pancreas (2016)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Mean changes in nutrient absorption were greater with pancrelipase versus placebo in patients with DM (CFA, 36.0% vs 7.5%, P < 0.0001; CNA, 33.4% vs 3.7%, P = 0.0002) and without DM (CFA, 25.2% vs 12.3%, P = 0.0326; CNA, 39.1% vs 17.6%, P = 0.1187).
Diabetes mellitus was not significantly associated with outcomes for CFA (P = 0.0802) and CNA (P = 0.2934).
Pancrelipase improved fat and protein absorption in patients with EPI due to chronic pancreatitis or pancreatectomy, with or without DM, and matched the safety profile previously reported.
16Weight gain and stool frequencyOpen-Labeln=51 · small study2011
Einfach gesagt: Pancrelipase was well tolerated over 6 months and resulted in statistically significant weight gain and reduced stool frequency in patients with EPI due to CP or PS previously managed with standard PERT.
Gubergrits N et al. · Alimentary pharmacology & therapeutics (2011)
The mean age was 50.9 years, 70.6% of patients were male, 76.5% had CP and 23.5% had undergone PS.
TEAEs were reported by 22 patients (43.1%) overall.
Only four patients (7.8%) had TEAEs that were considered treatment related.
17Nonverbal intellectual ability in autismRCTn=67 · small study2018
Einfach gesagt: Parents reported that the vitamin/mineral supplements, essential fatty acids, and HGCSF diet were the most beneficial.
Adams JB et al. · Nutrients (2018)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
There was a significant improvement in nonverbal intellectual ability in the treatment group compared to the non-treatment group (+6.7 ± 11 IQ points vs. -0.6 ± 11 IQ points, p = 0.009) based on a blinded clinical assessment.
Based on semi-blinded assessment, the treatment group, compared to the non-treatment group, had significantly greater improvement in autism symptoms and developmental age.
The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
Einfach gesagt: Indian Society of Gastroenterology.
Berry N et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2026)
Fat maldigestion occurs when lipase secretion falls to below 10% of normal.
This threshold is defined as severe PEI and is a definite indication for pancreatic enzyme replacement therapy (PERT).
In this review, we shall discuss about conditions, other than pancreatitis, which cause PEI, and understand the possible mechanisms by which they cause PEI.
19nutritional status and pancreatic functionÜbersicht2026
de Pretis N et al. · European journal of gastroenterology & hepatology (2026)
Not only pancreatic secretions but also the interaction between exocrine and endocrine pancreatic function have relevance on nutritional status, and there is increasing evidence that nutritional status impacts the prognosis of both inflammatory and pancreatic neoplastic diseases of the pancreas.
Signs of malnutrition need to be investigated and identified in patients with pancreatic diseases to optimize the medical management and, potentially, to improve the clinical outcome.
20Fat and nitrogen maldigestionRCTn=25 · very small study2010
Einfach gesagt: Pancrelipase delayed-release 12,000-lipase unit capsules were effective in treating fat and nitrogen maldigestion with a TEAE rate similar to that of placebo in patients with EPI due to CP or PS.
Whitcomb DC et al. · The American journal of gastroenterology (2010)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
In total, 25 patients (median age of 54 years, 76% male) received pancrelipase and 29 patients (median age of 50 years, 69% male) received placebo.
Th e mean ± s.d. change from baseline in CFA was significantly greater with pancrelipase vs. placebo: 31.9 ± 18.6 vs. 8.7 ± 12.4 % ( P < 0.0001) [corrected].
Treatment-emergent adverse events (TEAEs) were reported in five patients (20.0%) in the pancrelipase group and in six (20.7%) in the placebo group; the most common were gastrointestinal (GI) events and metabolism/nutrition disorders.